Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Colorectal Cancer (CRC) Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00165854
• Other study ID #: E7070-E044-209
• Secondary ID: 2004-002597-33
• Status: Completed
• Phase: Phase 2
• First received: September 13, 2005
• Last updated: June 26, 2014
• Start date: March 2003

Study information

• Verified date: October 2006
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Part 1 Inclusion Criteria:

• Histologically or cytologically confirmed solid tumour refractory to standard therapy or for whom no established therapy exists

• Age >= 18 years

• Karnofsky performance status of >= 70%

• Life expectancy of >= 3 months

• Absolute neutrophil count of >= 1.5 × 109/l, platelet count of ³ 100 × 109/l, haemoglobin level of ³ 10 g/dl (>= 6.2 mmol/l) (prior transfusion is permitted)

• Normal hepatic and renal function as defined by serum bilirubin £ 1.5 times the upper limit of normal, ALT and AST £ 2.5 times the upper limit of normal (£ 5 times the upper limit of normal in the presence of hepatic metastases), creatinine clearance ³ 50 ml/min (by Cockroft-Gault formula)

• Male and female patients

• Written informed consent to participate in the study

Part 1 Exclusion Criteria:

• More than two previous courses of documented myelosuppresive chemotherapy (epidermal growth factor targeted therapy does not constitute a course of chemotherapy)

• CNS metastases (a CT or MRI scan should be done if there is a clinical suspicion of CNS metastases)

• Major surgery, chemotherapy or radiation therapy (except palliative) within 4 weeks of treatment start

• Previous investigational cytotoxic treatment for malignant disease within 30 days before the start of the study

• Any treatment with non-oncological investigational drugs within 30 days before the start of the study

• Pregnancy or breast feeding (all women of childbearing potential must have a pregnancy test before inclusion in the study; post-menopausal women must be amenorrhoeic for at least 12 months). Female patients must use adequate contraceptive protection.

• Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection

• Uncontrolled infections

• Clinically significant cardiac impairment or unstable ischaemic heart disease including a myocardial infarction within three months of study entry

• History of alcoholism, drug addiction, or any psychiatric or psychological condition which in the opinion of the investigator would impair study compliance

• History of hypersensitivity to sulphonamides

• Prior severe or unexpected reaction to fluoropyrimidine therapy (which may be explained by dihydropyrimidine dehydrogenase deficiency or hypersensitivity to 5-FU)

• Malabsorption syndrome or other condition which may affect absorption of drug

• Concurrent or previous malignancy of a different tumour type within five years of starting the study except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia

• Treatment within two weeks before the start of the study with any of the following:

coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus, theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine

• Legal incapacity

Part 2 Inclusion Criteria:

• Ambulant patients with progressive metastatic CRC who have received prior treatment with 5 FU and irinotecan and/or oxaliplatin either as single agents or in combination. Either 5 FU and/or irinotecan and/or oxaliplatin may have been administered in the adjuvant setting or for the treatment of metastatic disease. Patients who have received both 5-FU and irinotecan or oxaliplatin in the adjuvant setting only must have experienced disease recurrence within one year of starting chemotherapy.

• At least one unidimensionally measurable lesion according to the RECIST criteria

• Age ³ 18 years

• Karnofsky performance status of ³ 70%

• Life expectancy of ³ 3 months

• Absolute neutrophil count of ³ 1.5 × 109/l, platelet count of ³ 100 × 109/l, haemoglobin level of ³ 10 g/dl (³ 6.2 mmol/l) (prior transfusion is permitted)

• Normal hepatic and renal function as defined by serum bilirubin £ 1.5 times the upper limit of normal, ALT and AST £ 2.5 times the upper limit of normal (£ 5 times the upper limit of normal in the presence of hepatic metastases), creatinine clearance ³ 50 ml/min (by Cockroft-Gault formula)

• Male and female patients

• Written informed consent to participate in the study

Part 2 Exclusion Criteria:

• Prior chemotherapy other than 5-FU, irinotecan and/or oxaliplatin

• CNS metastases (a CT or MRI scan should be done if there is a clinical suspicion of CNS metastases)

• Major surgery, chemotherapy or radiation therapy (except palliative) within 4 weeks of treatment start

• Previous investigational cytotoxic treatment for malignant disease within 30 days before the start of the study

• Any treatment with non-oncological investigational drugs within 30 days before the start of the study

• Pregnancy or breast feeding (all women of childbearing potential must have a negative pregnancy test before inclusion in the study; post-menopausal women must be amenorrhoeic for at least 12 months). Female patients must use adequate contraceptive protection.

• Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection

• Uncontrolled infections

• Clinically significant cardiac impairment or unstable ischaemic heart disease including a myocardial infarction within three months of study start

• History of alcoholism, drug addiction, or any psychiatric or psychological condition which in the opinion of the investigator would impair study compliance

• History of hypersensitivity to sulphonamides

• Prior severe or unexpected reaction to fluoropyrimidine therapy (which may be explained by dihydropyrimidine dehydrogenase deficiency or hypersensitivity to 5-FU)

• Malabsorption syndrome or other condition which may affect absorption of drug

• Concurrent or previous malignancy of a different tumour type within five years of starting the study except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia

• Treatment within two weeks before the start of the study with any of the following:

coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus, theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine

• Legal incapacity

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer (CRC)
• Colorectal Neoplasms

Intervention

Drug:
• E7070

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon
France	Institut Curie	Paris
Germany	Universitätsklinikum der GHS-Essen	Essen
Netherlands	Netherlands Cancer Institute	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Limited

Countries where clinical trial is conducted

France,  Germany,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the recommended dose of E7070 in combination with capecitabine by dose adjustment;
Primary	to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.
Secondary	Determine the pharmacokinetic profile of capecitabine and E7070 when administered in combination;
Secondary	measure duration of response and stable disease; to measure median and one year survival.